Clinical Trial Update: Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating intra- and postoperative administration of the trifunctional antibody catumaxomab in ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Catumaxomab (Removab) (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 | Status: COMPLETED